Percutaneous valve technologies have revolutionised the treatment of valvular heart disease (VHD) and emerged as an alternative treatment option in elderly patients at all levels of surgical risk. In 2019 and 2020, important advances in the field of valvular heart interventions were achieved. In this review, we present the most recent and relevant studies that have emerged on the transcatheter treatment of VHD in 2019 and 2020.
In August 2019, the U.S. Food and Drug Administration (FDA) approved the use of transcatheter aortic valve replacement (TAVR) for the treatment of symptomatic severe aortic stenosis (AS) in low-risk ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com